Key residues controlling phenacetin metabolism by human cytochrome P450 2A enzymes

Drug Metabolism and Disposition

Volumn 36, Issue 12, 2008, Pages 2582-2590

  DeVore, Natasha M ^a   Smith, Brian D ^a   Urban, Michael J ^a   Scott, Emily E ^a  

^a UNIVERSITY OF KANSAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN B1; COTININE; CYTOCHROME P450 2A; CYTOCHROME P450 2A13; CYTOCHROME P450 2A6; NICOTINE; PHENACETIN; UNCLASSIFIED DRUG;

ARTICLE; CRYSTAL STRUCTURE; DEALKYLATION; DISSOCIATION CONSTANT; DRUG METABOLISM; DRUG PROTEIN BINDING; ENZYME ACTIVE SITE; ENZYME SPECIFICITY; MICHAELIS MENTEN KINETICS; PRIORITY JOURNAL; STEREOCHEMISTRY;

AMINO ACID SUBSTITUTION; AMINO ACIDS; ARYL HYDROCARBON HYDROXYLASES; CATALYSIS; CATALYTIC DOMAIN; HUMANS; KINETICS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PHENACETIN; PROTEIN BINDING; RECOMBINANT PROTEINS; SPECTROPHOTOMETRY; STEROID HYDROXYLASES; SUBSTRATE SPECIFICITY;

EID: 57349177563     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.023770     Document Type: Article

References (29)

1. Bao Z, He XY, Ding X, Prabhu S, and Hong JY (2005) Metabolism of nicotine and cotinine by human cytochrome P450 2A13. Drug Metab Dispos 33:258-261.
2. Collaborative Computer Project, Number 4 (1994) The CCP4 suite: programs for protein crystallography. (1994) Acta Crystallogr D Biol Crystallogr 50:760-763.
3. DeLano WL (2002) The PyMOL Molecular Graphics System, DeLano Scientific, Palo Alto, CA.
4. Emsley P and Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60:2126-2132.
5. Evans P (2006) Scaling and assessment of data quality. Acta Crystallogr D Biol Crystallogr 62:72-82.
6. Fischbach T and Lenk W (1985a) Additional routes in the metabolism of phenacetin. Xenobiotica 15:149-164.
7. Fischbach T and Lenk W (1985b) The metabolism of N-hydroxyphenacetin in vitro and in vivo. Xenobiotica 15:915-927.
8. Flower RJ, Moncada S, and Vane JR (1985) Analgesic-antipyretics and anti-inflammatory agents, in Goodman and Gilman's The Pharmacological Basis of Therapeutics (Gilman AG, Gilman LS, Rall TW, and Murad G eds) pp 674-715, Macmillan, New York.
9. Fukami T, Katoh M, Yamazaki H, Yokoi T, and Nakajima M (2008) Human cytochrome P450 2A13 efficiently metabolizes chemicals in air pollutants: naphthalene, styrene, and toluene. Chem Res Toxicol 21:720-725.
10. Fukami T, Nakajima M, Sakai H, Katoh M, and Yokoi T (2007) CYP2A13 metabolizes the substrates of human CYP1A2, phenacetin, and theophylline. Drug Metab Dispos 35:335-339.
11. He XY, Shen J, Ding X, Lu AY, and Hong JY (2004a) Identification of critical amino acid residues of human metabolic activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-tobaccospecific carcinogen. Drug Metab Dispos 32:1516-1521.
12. 372 as critical amino acid residues for the activity difference between human CYP2A6 and CYP2A13 in coumarin 7-hydroxylation. Arch Biochem Biophys 427:143-153.
13. He XY, Tang L, Wang SL, Cai QS, Wang JS, and Hong JY (2006) Efficient activation of aflatoxin B1 by cytochrome P450 2A13, an enzyme predominantly expressed in human respiratory tract. Int J Cancer 118:2665-2671.
14. Kleywegt GJ and Jones TA (1994) Detection, delineation, measurement and display of cavities in macromolecular structures. Acta Crystallogr D Biol Crystallogr 50:178-185.
15. Laskowski RA, MacArthur MW, Moss DS, and Thornton JM (1993) PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Crystallogr 26:283-291.
16. Leslie AG (2006) The integration of macromolecular diffraction data. Acta Crystallogr D Biol Crystallogr 62:48-57.
17. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, and Read RJ (2007) Phaser crystallographic software. J Appl Crystallogr 40:658-674.
18. Murshudov GN, Vagin AA, and Dodson EJ (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53:240-255.
19. Nakajima M, Itoh M, Sakai H, Fukami T, Katoh M, Yamazaki H, Kadlubar FF, Imaoka S, Funae Y, and Yokoi T (2006) CYP2A13 expressed in human bladder metabolically activates 4-aminobiphenyl. Int J Cancer 119:2520-2526.
20. Negishi M, Uno T, Honkakoski P, Sueyoshi T, Darden TA, and Pedersen LP (1996) The roles of individual amino acids in altering substrate specificity of the P450 2a4/2a5 enzymes. Biochimie 78:685-694.
21. Sansen S, Hsu MH, Stout CD, and Johnson EF (2007a) Structural insight into the altered substrate specificity of human cytochrome P450 2A6 mutants. Arch Biochem Biophys 464:197-206.
22. Sansen S, Yano JK, Reynald RL, Schoch GA, Griffin KJ, Stout CD, and Johnson EF (2007b) Adaptations for the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure of human P450 1A2. J Biol Chem 282:14348-14355.
23. Schlicht KE, Michno N, Smith BD, Scott EE, and Murphy SE (2007) Functional characterization of CYP2A13 polymorphisms. Xenobiotica 37:1439-1449.
24. Smith BD, Sanders JL, Porubsky PR, Lushington GH, Stout CD, and Scott EE (2007) Structure of the human lung cytochrome P450 2A13. J Biol Chem 282:17306-17313.
25. Su T, Bao Z, Zhang QY, Smith TJ, Hong JY, and Ding X (2000) Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res 60:5074-5079.
26. Vriend G (1990) WHAT IF: a molecular modeling and drug design program. J Mol Graph 8:52-56, 29.
27. Wu ZL, Podust LM, and Guengerich FP (2005) Expansion of substrate specificity of cytochrome P450 2A6 by random and site-directed mutagenesis. J Biol Chem 280:41090-41100.
28. Yano JK, Hsu MH, Griffin KJ, Stout CD, and Johnson EF (2005) Structures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen. Nat Struct Mol Biol 12:822-823.
29. Zhang JY, Wang Y, and Prakash C (2006) Xenobiotic-metabolizing enzymes in human lung. Curr Drug Metab 7:939-948.